Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 850 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Benzodiazepine Clear all

Conditions: Hepatic Encephalopathy, Liver Cirrhosis
Interventions: Flumazenil, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: BMS-214662, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity
Interventions: PF-06882961, Rosuvastatin, Midazolam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Postoperative Nausea and Vomiting
Interventions: Olanzapine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Critical Illness
Interventions: Lorazepam, Midazolam, Lorazepam CI; Drug
Lead sponsor: The Emmes Company, LLC; Industry
Eligibility: 1 Day to 18 Years
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: BMS-214662, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: PF-07817883, Placebo, Midazolam, Moxifloxacin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia
Interventions: ASP4345, placebo, risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole, brexpiprazole, paliperidone, lurasidone; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 27
States / cities: Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more

Conditions: Depressive Disorder, Major
Interventions: Esketamine, Midazolam, Oral Placebo, Intranasal Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 12
States / cities: Birmingham, Alabama • New Haven, Connecticut • Washington D.C., District of Columbia + 9 more

Conditions: Tuberculosis
Interventions: Midazolam, PA-824; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: Drospirenone/Ethinylestradiol, Midazolam, JNJ-64530440; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Epilepsia Partialis Continua, Kojewnikov's Epilepsy, Epilepsy
Interventions: Clobazam, Clonazepam, Lorazepam; Drug
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Idiopathic Gastroparesis
Interventions: Olanzapine; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts • Ann Arbor, Michigan

Conditions: Schizophrenia
Interventions: ALK3831, Olanzapine, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 16
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Culver City, California + 13 more

Conditions: HPV
Interventions: Gardasil-9, Lidocaine injection, Lorazepam; Biological · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Colon Cancer, Rectal Cancer, Colonic Diverticulosis
Interventions: Fentanyl, Propofol, Midazolam; Drug
Lead sponsor: Trinity Health Michigan; Other
Eligibility: 18 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Major Depression, Generalized Anxiety Disorder
Interventions: quetiapine; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Landau-Kleffner Syndrome, Status Epilepticus, Electrographic
Interventions: Diazepam, Acetazolamide; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 3 Years to 12 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Psychotic Disorders
Interventions: Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 8 Years to 19 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 4
States / cities: Baltimore, Maryland • Glen Oaks, New York • Chapel Hill, North Carolina

Conditions: Solid Tumor
Interventions: cobimetinib, dextromethorphan, midazolam; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 4
States / cities: Los Angeles, California • Stanford, California • Detroit, Michigan + 1 more

Conditions: Drug Interactions, Drug Kinetics
Interventions: Alprazolam, Oxycodone, Placebo; Drug
Lead sponsor: Shanna Babalonis, PhD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Taking Benzodiazepines for Any Reason for 3 Months, Benzodiazepine Dependence
Interventions: EMPOWER-ED; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Adenotonsillitis, Tonsillitis
Interventions: Acetaminophen (paracetamol), Normal Saline Flush, Midazolam, Sevoflurane, Nitrous Oxide/Oxygen, Propofol, Morphine, Ondansetron, Dexamethasone; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 2 Years to 9 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Neonatal Abstinence Syndrome
Interventions: Clonidine HCL, saline; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 5 Days to 90 Days
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS

BMS-214662 in Treating Patients With Advanced Solid Tumors

Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

The Impact of Preoperative Olanzapine on Quality of Recovery After Discharge From Ambulatory Surgery

Lorazepam Sedation for Critically Ill Children

BMS-214662 in Treating Patients With Solid Tumors

A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam

Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440

Clobazam Use in Epilepsia Partialis Continua - Pilot Study

A Pilot Study on the Efficacy and Safety of Olanzapine in Gastroparesis

A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)

HPV Vaccine Reduced Dose

Compare Propofol to Fentanyl and Midazolam for Colonoscopy

Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines

Efficacy Study of Acetazolamide Versus Diazepam in Continuous Spike and Wave/Landau-Kleffner Syndrome

Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics

Study of Cobimetinib in Participants With Solid Tumors

Opioid Drug Interaction Study

Promoting Benzodiazepine Cessation Through an Electronically-delivered Patient Self-management Intervention

Analgesic Effect of IV Acetaminophen in Tonsillectomies

Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants